Stockscreener 앱 받기
63.75
2.83%
-1.86
전일 마감가:
$65.61
열려 있는:
$66.57
하루 거래량:
628.28K
Relative Volume:
1.09
시가총액:
$3.45B
수익:
$155.82M
순이익/손실:
$-40.42M
주가수익비율:
-89.79
EPS:
-0.71
순현금흐름:
$3.58M
1주 성능:
-2.27%
1개월 성능:
-4.24%
6개월 성능:
-4.34%
1년 성능:
+6.30%
1일 변동 폭
$63.46
$66.66
1주일 범위
$62.38
$67.00
52주 변동 폭
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
ACLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
63.75 | 3.45B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - MSN
Arcellx (ACLX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is Arcellx (ACLX) Poised to Capture Significant Market Share? - Yahoo Finance UK
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Large Increase in Short Interest - Defense World
(ACLX) Trading Advice - Stock Traders Daily
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention - Benzinga
Arcellx Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Arcellx Inc’s Anito-cel: A Promising Investment with Innovative Therapeutics and Market Potential - TipRanks
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Financial Snapshot: Analyzing Arcellx Inc (ACLX)’s Key Ratio Metrics - The Dwinnex
Arcellx (NASDAQ:ACLX) Shares Down 5.4%What's Next? - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 6.6% - MarketBeat
Taking a Closer Look At Arcellx Inc (ACLX) Following Its Recent Trade - Knox Daily
arcellx director kavita patel sells $96,854 in stock - MSN
Financial Review: Arcellx (NASDAQ:ACLX) versus C4 Therapeutics (NASDAQ:CCCC) - Defense World
arcellx director kavita patel sells $96,854 in stock By Investing.com - Investing.com Australia
(ACLX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - MarketBeat
Moody Aldrich Partners LLC Sells 16,122 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Analysts Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - Defense World
Vanguard Group Inc's Strategic Acquisition of Arcellx Inc Shares - GuruFocus.com
Stifel maintains Buy on Arcellx shares, target at $122 - MSN
Stifel maintains Buy on Arcellx shares, target at $122 By Investing.com - Investing.com Australia
(ACLX) On The My Stocks Page - Stock Traders Daily
Cantor Fitzgerald Estimates Arcellx FY2025 Earnings - Defense World
Brokers Issue Forecasts for Arcellx FY2025 Earnings - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Significant Growth in Short Interest - Defense World
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha
Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia
Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat
Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India
(ACLX)Analyzing Arcellx's Short Interest - Benzinga
Oversold Conditions For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat
Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcellx Inc 주식 (ACLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Elghandour Rami | SEE REMARKS |
Feb 07 '25 |
Option Exercise |
0.00 |
70,211 |
0 |
187,486 |
| Patel Kavita | Director |
Feb 04 '25 |
Option Exercise |
6.66 |
1,500 |
9,990 |
1,500 |
| Patel Kavita | Director |
Feb 04 '25 |
Sale |
64.57 |
1,500 |
96,855 |
0 |
| Patel Kavita | Director |
Jan 14 '25 |
Option Exercise |
6.66 |
1,500 |
9,990 |
1,500 |
| Patel Kavita | Director |
Jan 14 '25 |
Sale |
65.87 |
1,500 |
98,801 |
0 |
| Heery Christopher | CHIEF MEDICAL OFFICER |
Jan 03 '25 |
Option Exercise |
0.00 |
16,519 |
0 |
38,818 |
| Heery Christopher | CHIEF MEDICAL OFFICER |
Jan 07 '25 |
Sale |
75.53 |
4,230 |
319,485 |
28,638 |
| Heery Christopher | CHIEF MEDICAL OFFICER |
Jan 08 '25 |
Sale |
73.69 |
3,553 |
261,831 |
25,085 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 03 '25 |
Option Exercise |
0.00 |
15,339 |
0 |
38,834 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 07 '25 |
Sale |
75.68 |
14,012 |
1,060,474 |
13,579 |
0.27%
3.05%
자본화:
|
볼륨(24시간):